Skip to search formSkip to main contentSkip to account menu

davunetide

Known as: NAP peptide, NAPVSIPQ peptide 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (3)

AL 208AL-108AL-408

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Interventions in progressive supranuclear palsy.
2016
2016
University of Groningen Impairment of mitochondria dynamics by human A53T alpha-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease
2015
2015
NAP (davunetide) protects primary hippocampus culture by modulating expression profile of antioxidant genes during limiting oxygen conditions
Abstract Hypoxia is a well-known threat to neuronal cells and triggers the pathophysiological syndromes in extreme environments… 
2014
2014
NAP Reduces Murine Microvascular Endothelial Cells Proliferation Induced by Hyperglycemia
Hyperglycemia has been identified as a risk factor responsible for micro- and macrovascular complications in diabetes. NAP… 
Review
2013
Review
2013
Terapêutica farmacológica na doença de Alzheimer: progressos e esperanças futuras
it is estimated that over 24 million people suffer from dementia worldwide; in Portugal more than 150000 people are affected, and… 
Review
2011
Review
2011
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP… 
Highly Cited
2011
Highly Cited
2011
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model
Review
2010
Review
2010
FDA Pipeline preview, February 2010 (Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone, Davunetide, BiovaxID, EpiCept, CP-4126)
Recent FDA action (through February 2010) related to Ceftobiprole, Carglumic acid, Miglustat, Nebivolol, Myocet, Pirfenidone… 
2009
2009
Davunetide Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat
Davunetide or NAPVSIPQ is a neuroactive peptide which stabilizes microtubules and is currently in clinical development for… 
2009
2009
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy
NAP (NAPVSIPQ, generic name, davunetide), a neuroprotective peptide in clinical development for neuroprotection against Alzheimer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)